Quantcast
Channel: Triple Negative Breast Cancer, "I Won't Back Down!"
Viewing all articles
Browse latest Browse all 321

CDX-011 Study Gives Triple Negative Breast Cancer Patients New Hope

$
0
0
“This is the most promising phase 3 trial in triple negative breast cancer in the last five years, since the phase 3 trial with the PARP inhibitor iniparib,” says Cleveland Clinic oncologist and principal investigator Alberto Montero, MD. “CDX-011 is a novel targeted drug for a disease that is defined clinically by the absence of any targets. A potent chemotherapy is delivered in a targeted fashion by being attached to an antibody that recognizes GPNMB, which is overexpressed in about 25 to 30 percent of all triple negative breast cancers.”
Click link to read full article:
http://consultqd.clevelandclinic.org/2014/11/clinical-trial-tests-targeted-breast-cancer-therapy 

Viewing all articles
Browse latest Browse all 321

Trending Articles